Welcome to CIMBA

The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) was established in 2005. It was formed by a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers.

The aim of CIMBA is to provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers.

Currently, the Consortium consists of >85 different study groups, incorporating sites from Europe, North and South America, Australia, Asia and Africa. We have phenotype data for ~85,000 female and male BRCA1 and BRCA2 mutation carriers and to date ~43,000 have been genotyped for CIMBA projects with an additional ~20,000 currently undergoing genotyping.


CIMBA Coordination & Funding

Coordination of CIMBA is through the University of Cambridge and the QIMR Berghofer Medical Research Institute and, along with analytical efforts, is funded by Cancer Research UK (CRUK), the National Health and Medical Research Council of Australia (NHMRC) and the Gray Foundation.

CIMBA is supported by funding from Cancer Research UK programme grant (PPRPGM-Nov20\100002): CanRisk: Personalising cancer risk prediction for prevention and early detection.